Quest Diagnostics Q3 Adj EPS $2.22 Beats $2.19 Estimate, Sales $2.29B Beat $2.27B Estimate
Portfolio Pulse from Benzinga Newsdesk
Quest Diagnostics (NYSE:DGX) reported Q3 adjusted earnings of $2.22 per share, beating the analyst consensus estimate of $2.19 by 1.37 percent. However, this is a 5.93 percent decrease from the same period last year. The company also reported quarterly sales of $2.29 billion, beating the analyst consensus estimate of $2.27 billion by 1.10 percent, but this is a 7.68 percent decrease from the same period last year.
October 24, 2023 | 10:50 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Quest Diagnostics reported Q3 earnings and sales that beat estimates but were lower than the same period last year.
While Quest Diagnostics beat analyst estimates for Q3 earnings and sales, the figures were lower than the same period last year. This mixed result could lead to neutral short-term price movement for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100